Compass Pathways PLC

Change company Symbol lookup

Select an option...

CMPS Compass Pathways PLC

JPM-L JPMorgan Chase & Co

SBFM Sunshine Biopharma Inc

SEKEY Seiko Epson Corp

PXMD PaxMedica Inc

CDT Conduit Pharmaceuticals Inc

FUSN Fusion Pharmaceuticals Inc

RDUS Schnitzer Steel Industries Inc

ALEC Alector Inc

LZM Lifezone Metals Ltd

Go

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The Company is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.

ADR Fees

American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees